Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

44%

4 of 9 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 3

1(16.7%)

Phase 2

1(16.7%)

Phase 4

1(16.7%)

6Total

N/A(3)

Phase 3(1)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06649032Completed

Survey of Incidence of Respiratory Tract Infections

Role: lead

NCT06582589Phase 2Completed

HEALSea Nasal Spray for Prevention of Infections in Children

Role: lead

NCT06613906Not ApplicableCompleted

Prevention With Healsea in Adults Against Respiratory Infection Study

Role: lead

NCT05034328Completed

Symbiofilm Trial in Allergic Kids (SYMBIOFILM-TAK)

Role: lead

NCT05015530Completed

Impact of Symbiofilm On Nasal Microbiota

Role: lead

NCT05819203Not ApplicableCompleted

BАbykids Spray In Common Cold

Role: lead

NCT05819190Not ApplicableCompleted

Testing the Efficacy in Adults With Cold of HEalsea Rescue*

Role: lead

NCT02541331Phase 3Completed

Efficacy Of Bacterial Lysate In Asthmatic Children

Role: lead

NCT02417649Phase 4Completed

Advanced Immunological Approach in COPD Exacerbation

Role: lead

All 9 trials loaded